NCT05940272
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers No drug interventions other Not Available recruiting NCT06356129
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma treatment 3 recruiting NCT06610344
BHB & CAR-T for Lymphomas No drug interventions treatment Not Available not_yet_recruiting NCT03960840
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL treatment 1 / 2 recruiting NCT05887167
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells with Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects with Relapsed/Refractory Hematological Malignancies No drug interventions treatment 1 recruiting NCT06500273
Consolidation of First-Line MRD+ Remission with Cema-cel in Patients with LBCL treatment 2 recruiting NCT05794958
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel treatment 1 recruiting NCT06047080
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma treatment 3 recruiting NCT06285422
Study Evaluating SC262 in Subjects with R/r Non-Hodgkin's Lymphoma (VIVID) treatment 1 recruiting NCT06544265
SynKIR-310 for Relapsed/Refractory B-NHL No drug interventions treatment 1 recruiting NCT06593145
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms No drug interventions treatment 1 recruiting NCT06486051
A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma treatment 2 recruiting NCT05108805
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting No drug interventions supportive_care Not Available active_not_recruiting NCT06071871
A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma treatment 2 recruiting NCT05020678
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers No drug interventions treatment 1 recruiting NCT05643742
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies No drug interventions treatment 1 / 2 recruiting NCT05648019
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol No drug interventions treatment 2 recruiting NCT05820841
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma treatment 3 recruiting NCT06550141
Emapalumab Prevention of CAR-T Cell Associated Toxicities treatment 2 not_yet_recruiting NCT06567366
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors treatment 2 not_yet_recruiting NCT05665062
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies treatment 1 recruiting NCT04690192
CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma treatment 1 / 2 active_not_recruiting NCT06104592
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL No drug interventions treatment 2 recruiting NCT05429268
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) treatment 3 recruiting NCT05472610
Study of Efficacy of BZ019 in Large B-cell Lymphoma No drug interventions treatment 2 unknown_status NCT04503538
Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity No drug interventions supportive_care Not Available withdrawn NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies treatment 1 / 2 not_yet_recruiting NCT06375733
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL treatment 1 / 2 recruiting NCT06045247
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma treatment 2 recruiting NCT06343311
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) No drug interventions treatment 1 / 2 recruiting NCT04566978
89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) diagnostic 0 active_not_recruiting NCT06142188
Relmacabtagene Autoleucel in Hematologic Malignancies Not Available Not Available not_yet_recruiting NCT05377307
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy No drug interventions Not Available Not Available recruiting NCT06479356
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma treatment 2 recruiting NCT06167785
A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T treatment 2 not_yet_recruiting NCT05757700
Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma No drug interventions treatment 1 recruiting NCT06142175
Relmacabtagene Autoleucel in Patients With LBCL Not Available Not Available recruiting NCT05464719
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy treatment 2 recruiting NCT04250324
Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma No drug interventions treatment 1 unknown_status NCT04889716
CAR-T Followed by Bispecific Antibodies treatment 2 recruiting NCT05929716
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma treatment 2 withdrawn NCT05404048
PD-L1 PET-imaging During CAR T-cell Therapy No drug interventions diagnostic 2 recruiting NCT03642626
MT2017-45: CAR-T Cell Therapy for Heme Malignancies Not Available Not Available active_not_recruiting NCT05776160
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel Not Available Not Available available NCT06567080
JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases No drug interventions treatment 1 not_yet_recruiting NCT05733650
Expanded Access Program for Epcoritamab Not Available Not Available approved_for_marketing NCT05326243
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma No drug interventions treatment 1 / 2 recruiting NCT03188198
Risk Adapted Therapy in Diffuse Large B Cell Lymphoma treatment 2 unknown_status NCT00118209
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma treatment 3 completed